| Trial ID: | L3111 |
| Source ID: | NCT01088165
|
| Associated Drug: |
Adalimumab Treatment Arm
|
| Title: |
The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis
|
| Acronym: |
CASTIP
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Psoriasis|Cardiovascular Diseases|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Adalimumab treatment arm|DRUG: Fumaric acid esters treatment group|OTHER: Narrow band UVB radiation
|
| Outcome Measures: |
Primary: The influence of adalimumab treatment in comparison to treatment with fumaric acid esters on the functional integrity of the endothelium will be monitored by flow mediated dilatation (FMD), 3 and 6 months | Secondary: The measurement of carotid artery intima-media thickness (IMT) by ultrasound will serve as a morphological substrate for evaluating the potential effect of adalimumab on signs of atherosclerosis within the vessel wall, 3 and 6 months|Influence of adalimumab in comparison to fumaric acid esters on biochemical cardiovascular and metabolic risk factors, 3 and 6 months
|
| Sponsor/Collaborators: |
Sponsor: Medical University of Vienna
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2010-05
|
| Completion Date: |
2014-05
|
| Results First Posted: |
|
| Last Update Posted: |
2012-01-20
|
| Locations: |
Medical University Vienna Dpt. of Dermatology, Vienna, 1090, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT01088165
|
